ABSTRACT
We report the clinical symptoms and examination findings of Mycoplasma genitalium (MG) in women living with human immunodeficiency virus in South Africa. If we relied on syndromic management alone to treat MG, only 15 of 46 MG-infected women would have received. appropriate treatment: sensitivity of 32.6% (95% confidence interval, 19.5-48.0) and specificity of 67.4% (95% confidence interval, 63.4-71.2).
Subject(s)
HIV Infections/epidemiology , Mycoplasma Infections/diagnosis , Mycoplasma Infections/epidemiology , Mycoplasma genitalium/isolation & purification , Adult , Anti-Bacterial Agents/therapeutic use , Coinfection/diagnosis , Coinfection/drug therapy , Coinfection/epidemiology , Coinfection/pathology , Female , Humans , Middle Aged , Molecular Diagnostic Techniques , Mycoplasma Infections/drug therapy , Mycoplasma Infections/pathology , Mycoplasma genitalium/drug effects , Mycoplasma genitalium/genetics , Sexually Transmitted Diseases/diagnosis , Sexually Transmitted Diseases/drug therapy , Sexually Transmitted Diseases/epidemiology , Sexually Transmitted Diseases/pathology , South Africa/epidemiologyABSTRACT
This prospective cohort study of 622 women living with human immunodeficiency virus (HIV) from Johannesburg (2012) detected Mycoplasma genitalium in 7.4% (95% confidence interval [CI]: 5.5-9.7, 46/622), with detection more likely with lower CD4 counts(adjusted odds ratio [AOR] 1.02 per 10 cells/µL decrease, 95% CI: 1.00-1.03) and higher plasma HIV-1 RNA (AOR 1.15 per log copies/mL increase, 95% CI: 1.03-1.27). No mutations for macrolide/quinolone resistance was detected.
